Abstract
Transition metal complexes with terpyridine ligands have attracted a widespread interest with respect to biomedical applications: [(tpy)PtCl]Cl and [(tpy)RuCl3] are potent anti-tumor agents with activities comparable to those of cisplatin and carboplatin. The RuII complexes feature a high potential as reactive probes for DNA oxidation; whereas, luminescent IrIII, PtII or EuIII complexes have been utilized in biolabeling applications. Besides complexes based on heavy second or third row transition metal ions, remarkable results have been obtained with respect to the development of new types of metallodrugs, based on the naturally more abundant and intrinsically less toxic first row transition metal ions (e.g. FeII, CuI/II, ZnII). The perspective of these complexes in particular with respect to future biomedical applications in chemotherapy and cleavage of nucleic acids is evaluated in this review.
Keywords: Cytotoxicity, DNA cleavage, metallodrugs, self-assembly, supramolecular chemistry, terpyridine complexes, Transition metal complexes, DNA oxidation, nucleic acids, chemotherapy, carboplatin, superoxide dimutase, stereospecific transformations, potential metallodrugs
Current Topics in Medicinal Chemistry
Title: Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules
Volume: 12 Issue: 3
Author(s): Andreas Winter, Michael Gottschaldt, George R. Newkome and Ulrich S. Schubert
Affiliation:
Keywords: Cytotoxicity, DNA cleavage, metallodrugs, self-assembly, supramolecular chemistry, terpyridine complexes, Transition metal complexes, DNA oxidation, nucleic acids, chemotherapy, carboplatin, superoxide dimutase, stereospecific transformations, potential metallodrugs
Abstract: Transition metal complexes with terpyridine ligands have attracted a widespread interest with respect to biomedical applications: [(tpy)PtCl]Cl and [(tpy)RuCl3] are potent anti-tumor agents with activities comparable to those of cisplatin and carboplatin. The RuII complexes feature a high potential as reactive probes for DNA oxidation; whereas, luminescent IrIII, PtII or EuIII complexes have been utilized in biolabeling applications. Besides complexes based on heavy second or third row transition metal ions, remarkable results have been obtained with respect to the development of new types of metallodrugs, based on the naturally more abundant and intrinsically less toxic first row transition metal ions (e.g. FeII, CuI/II, ZnII). The perspective of these complexes in particular with respect to future biomedical applications in chemotherapy and cleavage of nucleic acids is evaluated in this review.
Export Options
About this article
Cite this article as:
Winter Andreas, Gottschaldt Michael, R. Newkome George and S. Schubert Ulrich, Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules, Current Topics in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/156802612799078919
DOI https://dx.doi.org/10.2174/156802612799078919 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deoxypodophyllotoxin Isolated from Juniperus communis Induces Apoptosis in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment
Current Medicinal Chemistry Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Study of Cancer Cell Lines with Fourier Transform Infrared (FTIR)/ Vibrational Absorption (VA) Spectroscopy
Current Physical Chemistry Efficient Green Synthesis of Bis(3-indolyl)phenylmethanes Catalyzed by 1- (Benzenesulfonyl)-3-methyl-1H-imidazolium Chlorides
Letters in Organic Chemistry Synthesis and Biological Evaluation of a Series of 2-(Substitutedphenyl) benzothiazoles
Medicinal Chemistry Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Patent Selections:
Current Biomarkers (Discontinued) Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Cytotoxic Nitrobenzoyloxy-substituted Sesquiterpenes from Spongederived Endozoic Fungus Aspergillus insulicola MD10-2
Current Pharmaceutical Biotechnology HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Mechanisms of Resistance to Chemotherapy in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Current Treatment for Cervical Cancer: An Update
Anti-Cancer Agents in Medicinal Chemistry Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry